Connect with us

Government

Goldman Releases 2022 Stock Forecast: Diverges With A Bearish Morgan Stanley, Sees S&P Rising To 5,100

Goldman Releases 2022 Stock Forecast: Diverges With A Bearish Morgan Stanley, Sees S&P Rising To 5,100

One day after the increasingly grouchy Morgan Stanley published its 2022 equity market outlook, in which it predicted that the S&P.

Published

on

Goldman Releases 2022 Stock Forecast: Diverges With A Bearish Morgan Stanley, Sees S&P Rising To 5,100

One day after the increasingly grouchy Morgan Stanley published its 2022 equity market outlook, in which it predicted that the S&P would close the coming year at 4,400, some 6% lower from current levels, as a result of multiple contraction emerging from higher yields and urged clients to exit the US and instead focus on Europe and Japan, Goldman overnight published its own far more cheerful view on where stock will trade in the coming years.

In keeping with its traditional bullishness, and with the S&P having recently surpassed the bank's 2021 year-end price target of 4,700, there was little downside for the bank's chief equity strategist David Kostin to continue the levitating autopilot, and he did just that, forecasting that the S&P 500 will climb by 9% to 5100 at year-end 2022, "reflecting a prospective total return of 10% including dividends."

With multiples already stretched, Goldman said that profit growth - which accounted for the entire S&P 500 return in 2021 - will continue to drive gains in 2022. It sees S&P 500 EPS will rising 8% to $226 in 2022 and by 4% to $236 in 2023 (the bank's EPS estimate is 2% above 2022 bottom-up consensus). Curiously, with companies consistently expanding profit margins despite input cost pressures and supply chain challenges, Goldman expects profit margins to rise another 40 bps to 12.6% in 2022 before declining by 20 bp in 2023 due to corporate tax reform.

Of course, Goldman's base case will likely be wrong (as was its forecast in Nov 2020 when the bank forecast the S&P rising to "only" 4,300 despite predicting a "Roaring '20s Redux"), and so it has also supplied two alternative projections: i) a faster growth and lower inflation than expected, would lift the S&P 500 to 5500, 17% above the current level; ii) Slower growth and higher inflation would reduce the S&P 500 by 25% to 3500. With the Fed set to hike at least twice in 2022, our money is on the latter, unless of course a market crash some time in the H2 of 2022 spooks the Fed and it promptly is forced to unwind its tightening.

And speaking of multiples, Goldman forecasts that the S&P 500 P/E multiple will remain roughly flat, ending 2022 at 21.6x, especially since after two years of near-zero interest rates, the Fed will likely begin hiking in July. And while 10-year Treasury yields will rise to 2% by the end of next year, Goldman believes that this will be offset by a declining Equity Risk Premium as policy uncertainty declines and consumer confidence rises. Strong corporate and household demand for equities will help support valuation.

(TL/DR): here are Goldman's official client-facing Investment Strategies (for what the bank's trading desk will actually be doing with the firm's, and clients' money, check back in a few days):

  1. Own virus- and inflation-sensitive cyclicals;
  2. Avoid high labor cost firms;
  3. Buy growth stocks with high margins vs. low margin or unprofitable growth stocks. Overweight Technology, Financials, and Health Care

For those curious for more, below is the investment summary section excerpted from the note:

For the last 30 years, declining interest rates have accompanied both rising equity valuations and higher corporate profit margins. The last 20 months have been no exception. The Fed responded to the pandemic by flooding financial markets with liquidity and pushing the funds rate to zero. Since the March 2020 trough, the S&P 500 index has more than doubled in a nearly uninterrupted upward trajectory to reach its current all-time high.

But the 2022 investment environment will be different in several important respects from the past two years. One aspect that will change next year is that the Fed will begin to hike rates in July. Real interest rates will also rise, solidifying the ceiling on valuation multiples and driving rotations within the equity market.

However, other aspects of the current equity market will persist. Real rates, while rising, will remain negative, and investor equity allocations will continue to establish record highs. In contrast with our expectation during the past year, corporate tax rates will likely remain unchanged in 2022 and rise in 2023. Or, as Kostin summarized it "Corporate earnings will grow and lift share prices. The equity bull market will continue." We'll see about that, but for now, here are Goldman's key assumptions:

  • PRICE: We forecast the S&P 500 index will climb by 9% to 5100 at year-end 2022, reflecting a prospective total return of 10% including dividends. Decelerating economic growth, a tightening Fed, and rising real yields suggest investors should expect modestly below-average returns next year. The S&P 500 has historically generated an average 12-month return of 8% in environments of positive but slowing economic activity and rising real interest rates, which describes our economists’ forecast for 2022. Counter to the intuition of many investors, the stellar 26% YTD return is not a good reason in itself to expect a weak return in 2022. Since 1900, the S&P 500 has generated an average 12-month return of 10%. Returns have actually averaged slightly better than that (+11%) following 12-month gains exceeding 20%, and only slightly lower (+9%) following 24-month gains exceeding 50%.
  • SALES & EARNINGS: Earnings growth has accounted for the entire S&P 500 return in 2021 and will continue to drive gains in 2022. S&P 500 EPS will grow by 8% in 2022 to $226 and by 4% in 2023 to $236. Aggregate sales for S&P 500 index will rise by 9% in 2022 and 5% in 2023. Based on the current reconciliation framework, we assume Congress will enact tax reform legislation, but the increase in the effective corporate tax rate will occur in 2023 rather than in 2022. If the existing tax law is unchanged, it would add 200 bp to our 2023 EPS growth rate (4% vs. 6%) and our EPS forecast would equal $241.
  • PROFIT MARGINS: We estimate that S&P 500 net margins will increase by 41 bp to 12.6% in 2022 before tax hikes compress margins by 18 bp to 12.4% in 2023. No near-term solutions exist to solve the supply chain and input cost problems that plague so many industries. However, managements have used price increases, cost controls, and technology to preserve margins, and many of the headwinds will ease in 2022. However, a tight labor market will persist and drive wage inflation. Our commodities research colleagues forecast Brent crude oil will peak at $90/bbl in early 2022 and then decline to $80 by year-end. Our economists expect annualized US GDP growth will decelerate from 4.5% in 1Q to 1.8% in 4Q 2022. During the same time, core PCE inflation will subside from 4.3% in 1Q to 2.4% by year-end.
  • VALUATIONS: Gradually rising interest rates will offset an Equity Risk Premium that declines but remains wider than its long-term average, keeping the P/E multiple roughly flat at 21.6x at year-end 2022. The valuation of both the median S&P 500 stock and the aggregate index rank in the 90th+ percentile vs. history on a wide range of metrics ranging from P/E, to EV/sales, to EV/EBITDA, and P/B. However, the yield gap between the S&P 500 earnings yield (4.6%) and the ten-year Treasury note yield (1.6%) currently equals 301 bp, ranking in the 40th percentile vs. history. Our Dividend Discount Model-implied ERP of 5% ranks in the 30th percentile. We expect that declining policy uncertainty and rising consumer confidence will lower it to 4.6% by year-end 2022.
  • MONEY FLOW: Households and corporations will be the key sources of demand for US equities in 2022. Households own half of the $28 trillion in US cash assets, an increase of $3 trillion since before the pandemic. We expect households will shift some of this capital into equities over time. On the corporate side, cash/asset ratios stand at record highs, and this year has witnessed record buyback authorizations exceeding $1 trillion. Foreign investors will also be net buyers ($100 billion) while mutual and pension funds will collectively be net sellers of $400 billion.
  • ALTERNATIVE SCENARIOS: (1) Faster growth and lower inflation than we expect would lift the S&P 500 to 5500, 17% above the current level. (2) Slower growth and higher inflation would reduce the S&P 500 by 25% to 3500. Supply chain disruptions and inflation pressures easing more quickly than currently assumed together with strong consumer demand would support 10% EPS growth in 2022. While interest rates would rise, so would valuation multiples. Alternatively, worse-than-expected inflation pressures could weigh on consumer demand, damage profit margins, and lead to a more aggressive Fed than currently priced. This would lead to zero earnings growth in 2022 alongside a large decline in valuations. As our economists have highlighted, a key risk for US equities looking beyond 2022 will be a higher terminal fed funds rate than currently implied by markets.
  • MARKET STRUCTURE: The highest degree of equity market concentration in decades means the path of the S&P 500 will be tied to the fates of its largest stocks. The “FAAMG” companies (FB, AAPL, AMZN, MSFT, GOOGL) account for 23% of S&P 500 market cap and 17% of earnings. These firms’ strong secular revenue growth, high profit margins, and elevated reinvestment rates have helped lift them to the top of the index. However, shifting tax and regulatory policy has increased the idiosyncratic risk these companies face, and therefore also the idiosyncratic risk borne by investors in the broad US equity market.
  • INVESTMENT STRATEGIES: Own virus-sensitive cyclicals; avoid high labor cost firms; profitable vs. unprofitable growth stocks. (1) Own cyclicals, including “re-opening” stocks and those exposed to recent input cost headwinds that will benefit from accelerating economic growth in early 2022; (2) Avoid companies with elevated labor cost exposure given a tightening jobs market with the strongest wage growth in decades; (3) Own highly profitable long duration growth stocks and avoid fast-growing firms valued entirely on long-term growth expectations, which will be more vulnerable to the risk of rising interest rates or disappointing revenues.
  • SECTOR RECOMMENDATIONS: Our earnings forecasts coupled with our macro model indicate investors should overweight the Info Tech, Financials, and Health Care sectors. Raise Financials to overweight on expectations of rising interest rates and strong economic growth in the first half of the year. Raise Health Care to overweight as declining policy uncertainty should help close the sector’s record valuation discount. Maintain long-term overweight in Information Technology on strong secular growth, high margins, and valuations in line with historical averages. Underweight “bond proxy” Consumer Staples, Utilities, and Telecom Services as well as the expensive Autos industry group.

A snapshot of the bank's various scenarios:

In terms of macro assumptions, Goldman's economists expect strong but decelerating US and global economic growth in 2022. Based on the bank's top-down model, US economic growth accounts for roughly 50% of the variability in annual EPS growth. Kostin calculates that each 1% increase in GDP growth translates to roughly $7 of S&P 500 EPS; the bank's macro earnings model also assumes the labor market will continue to tighten, 2-year and 10-year interest rates will rise gradually, and oil prices will decline by year-end 2022 after peaking at $90/bbl early next year.

Some more on Goldman's earnings forecasts, which the bank sees rising by 8% to $226 in 2022, an increase of $14 from its previously published estimate of $212, and is driven by the bank's expectations for continued margin expansion (this is where Goldman and Morgan Stanley differ greatly in their outlooks) as well as a "smaller-than-expected tax reform impact that should take effect in 2023 rather than in 2022."

We lift our 2021 EPS estimate by $2 to $209 (+47%) to incorporate better-than-expected realized EPS growth in 3Q. We also raise our 2023 estimate by $10 to $236, reflecting 4% annual growth. The upward revisions can be attributed to our expectations of additional organic margin expansion and a smaller-than-expected tax reform impact that should take effect in 2023 rather than in 2022, as we previously expected.

Goldman's top-down estimates are roughly 2% above consensus bottom-up estimates in 2021 and 2022 but below consensus in 2023, even excluding tax reform. Consistent with the recent trend, Goldman believes that analysts remain too conservative with their near-term forecasts, "as companies continue to leverage pricing power and cost reductions to withstand rising material and wage costs." However, outside of post-recession recoveries, analysts are typically too optimistic with their forecasts, and Goldman (which is certainly subject to this optimism bias) expects this dynamic to resume by late 2022. The median revision to consensus EPS estimates during the last 30 years has been -8% (-4% annually).

Goldman also laid out its revised tax expectations, which now assume that corporate tax reform will reduce 2023 S&P 500 EPS by roughly 2-3% relative to constant tax policy. The Build Back Better framework indicated that most of the corporate tax provisions will take effect in 2023, not 2022 as previously assumed. Under current tax policy, Goldman forecasts 2023 EPS of $241 (+6% year/year growth). However, our new base case assumes the implementation of a 15% minimum book tax rate and a 15% “GILTI” tax rate on foreign income, which results in our revised 2023 EPS estimate of $236 (+4% year/year growth). Note that if passed, the proposed buyback excise tax would be accounted for as a reduction in equity, not a tax expense on the income statement, and therefore would have a de minimis impact on EPS.

From a sector perspective, Kostin expects that Information Technology earnings will face the largest headwind from tax reform. The tax proposals focus on firms with low effective tax rates and high foreign income which encompass many Information Technology and Health Care companies. The median Info Tech company has a consensus 2023 effective tax rate of 16%, with 34% of companies (representing 29% of aggregate Info Tech EPS) expected to have effective tax rates below the 15% threshold.

* * *

Finally, looking closer at valuation, Goldman expects that rising interest rates will be offset by equity risk premium (ERP) compression and lead to a roughly flat forward P/E multiple in 2022. Goldman economists expect the nominal 10-year US Treasury yield will rise to 2.0% by year-end 2022, driven primarily by increasing real rates. If this forecast is realized, both nominal and real interest rates would still remain low by historical standards and continue to support the relative attractiveness of equities. The bank's ERP model includes changes in 10-year breakeven inflation, the 10s2s slope of the yield curve, consumer confidence, policy uncertainty, and the size of the Fed balance sheet. Kostin forecasts the ERP will decline to 4.6% by year-end 2022 from 5.0% currently as investors gain clarity and confidence regarding the inflation and fiscal policy outlooks. This would still register modestly above the 45-year average.

Combining Goldman's interest rate assumptions and its ERP model imply a forward P/E multiple of 21.6x at year-end 2022 compared with 21.8x today. As Kostin admits, the start of a Fed hiking cycle, rising real rates, and a decelerating economic growth environment suggest further absolute valuation expansion is unlikely, which is why Goldman is confined to forecasting EPS growth as the driver of higher stock prices. Even so, at 21.6x, the P/E multiple would rank in the 93rd percentile vs. history in absolute terms. However, relative equity valuations vs. US Treasury yields would still register as attractive compared with historical averages (46th percentile).

In effect, this entire note boils down to two things: the Fed model, i.e., rates are so low so investors have to buy stocks... and FOMO, or there is nothing else all that money sloshing around can buy. Focusing on the first, the chart below provides a sensitivity of S&P 500 forward P/E multiples to various interest rate and ERP scenarios. Investors remain focused on the prospect for a sharp, sustained rise in bond yields. The drivers of higher rates will determine the corresponding change in the ERP and the ultimate impact on the S&P 500 index level: Rising rates driven by an improving growth outlook would likely correspond with a declining ERP and represent less of a headwind to valuation than a large rise in real interest rates driven by a hawkish shift from the Fed. Of course, if the economy were to contract sharply then this pillar of Goldman's forecast will be useless.

Those who wish to pick bones with Goldman's forecast can do so with the next assumption namely that "the upcoming rate hikes will not derail the bull market, but the historical experience during Fed tightening cycles suggests further valuation expansion is unlikely." Current futures market pricing anticipates a path of Fed tightening roughly in line with the bank economists’ expectations, for liftoff in mid-2022 (this was pulled forward by an entire year just a few weeks ago) and two total hikes in each of 2022 and 2023. Looking at the previous five Fed hiking cycles, P/E multiples were roughly flat from 6 months prior to 6 months after the first Fed hike. As Kostin notes, the path of multiples varied beyond the 6-month mark, highlighting the importance of the length and magnitude of the tightening cycle. Although the bank's economists and rates strategists believe that policy rates will eventually exceed current market pricing, they expect the market to adopt that view gradually and do not expect a sharp repricing of rates in 2022. The risk is that should inflation persist, this is the weakest argument behind Goldman's optimistic forecast.

This, then, brings us to the second and perhaps most important assumption behind Goldman's optimistic outlook: the absence of attractive alternatives, which means investor allocations to equities should rise further into uncharted territory in 2022 (unless of course allocations to cryptos and other alternative assets take their place). According to Goldman calculations, nearly $220 billion has flowed into US equity mutual funds and ETFs YTD, a pace that will set a new annual record. Along with strong equity market appreciation, these inflows helped to lift the aggregate equity allocation of households, foreign investors, mutual funds and pension funds (collective owners of 84% of the US equity market) to a record 53% of their combined financial assets. According to Kostin, the alternatives to stocks are "understandingly unappealing" (we assume this includes cryptos which for those who can hold on to the volatility rollercoaster, is certainly not the case), with the return on cash effectively zero, the yield on 10-year US Treasury note just 1.6%, and tight IG and HY corporate bond spreads. As Goldman concludes, equity allocations typically increase most when consumer confidence increases, policy uncertainty declines, and growth expectations rise, suggesting that a strong 2022 macro environment could further support rising allocations.

In other words, continued low rates and FOMO will keep pushing stocks higher for another year.

* * *

One final point,here are Goldman's sector recommendations:

  • Goldman recommends investors increase their exposures to Health Care and Financials from Neutral to Overweight and reiterates its Overweight allocation to Info Tech (translation: Goldman's market desk will be selling these sectors to clients). Financials should benefit from strong US and global economic activity in early 2022 and the rise in interest rates that our economists expect next year. Health Care trades at depressed valuations that should recover as political risk eases. In addition, it is a rare sector that typically outperforms in environments when real rates drive nominal rates higher, which describes our economists’ forecasts for most of 2022: "We have maintained a long-term overweight position in the Info Tech sector since December 2016 and continue to find its elevated profit margins and secular growth profile attractive at valuations that appear reasonable relative to its fundamentals."
  • Goldman also recommends Underweight allocations to the Consumer Staples and Utilities sectors as well as to the Autos & Components industry group within Consumer Discretionary and Telecom Services within the Communication Services sector (again, this is what Goldman will be buying from its clients). Goldman economists’ forecast strong 4.0%+ annualized US GDP growth during the first half of 2022 suggests it is too early for investors to fully rotate into defensive sectors. Consumer Staples, Utilities, and Telecom Services generally struggle to outperform the index as interest rates climb. Within Consumer Discretionary, Automobiles & Components has historically been challenged in periods where growth was decelerating and rates were rising, as our economists expect will happen next year. The sector has recently outperformed and trades at an elevated valuation vs. history, suggesting it has already priced some improvement in supply chains.
  • Investors should neutral-weight a variety of cyclical sectors including Materials, Real Estate, Industrials, and Energy. Goldman also recommends a neutral weighting to the Media & Entertainment industry group within the Communication Services sector as well as Consumer Durables & Apparel, Consumer Services, and Retailing within Consumer Discretionary

There is much more in the full report which is available to pro subs, and can be found in the usual space.

Tyler Durden Tue, 11/16/2021 - 16:30

Read More

Continue Reading

Government

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19…

Published

on

Fauci Deputy Warned Him Against Vaccine Mandates: Email

Authored by Zachary Stieber via The Epoch Times (emphasis ours),

Mandating COVID-19 vaccination was a mistake due to ethical and other concerns, a top government doctor warned Dr. Anthony Fauci after Dr. Fauci promoted mass vaccination.

Coercing or forcing people to take a vaccine can have negative consequences from a biological, sociological, psychological, economical, and ethical standpoint and is not worth the cost even if the vaccine is 100% safe,” Dr. Matthew Memoli, director of the Laboratory of Infectious Diseases clinical studies unit at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), told Dr. Fauci in an email.

“A more prudent approach that considers these issues would be to focus our efforts on those at high risk of severe disease and death, such as the elderly and obese, and do not push vaccination on the young and healthy any further.”

Dr. Anthony Fauci, ex-director of the National Institute of Allergy and Infectious Diseases (NIAID. in Washington on Jan. 8, 2024. (Madalina Vasiliu/The Epoch Times)

Employing that strategy would help prevent loss of public trust and political capital, Dr. Memoli said.

The email was sent on July 30, 2021, after Dr. Fauci, director of the NIAID, claimed that communities would be safer if more people received one of the COVID-19 vaccines and that mass vaccination would lead to the end of the COVID-19 pandemic.

“We’re on a really good track now to really crush this outbreak, and the more people we get vaccinated, the more assuredness that we’re going to have that we’re going to be able to do that,” Dr. Fauci said on CNN the month prior.

Dr. Memoli, who has studied influenza vaccination for years, disagreed, telling Dr. Fauci that research in the field has indicated yearly shots sometimes drive the evolution of influenza.

Vaccinating people who have not been infected with COVID-19, he said, could potentially impact the evolution of the virus that causes COVID-19 in unexpected ways.

“At best what we are doing with mandated mass vaccination does nothing and the variants emerge evading immunity anyway as they would have without the vaccine,” Dr. Memoli wrote. “At worst it drives evolution of the virus in a way that is different from nature and possibly detrimental, prolonging the pandemic or causing more morbidity and mortality than it should.”

The vaccination strategy was flawed because it relied on a single antigen, introducing immunity that only lasted for a certain period of time, Dr. Memoli said. When the immunity weakened, the virus was given an opportunity to evolve.

Some other experts, including virologist Geert Vanden Bossche, have offered similar views. Others in the scientific community, such as U.S. Centers for Disease Control and Prevention scientists, say vaccination prevents virus evolution, though the agency has acknowledged it doesn’t have records supporting its position.

Other Messages

Dr. Memoli sent the email to Dr. Fauci and two other top NIAID officials, Drs. Hugh Auchincloss and Clifford Lane. The message was first reported by the Wall Street Journal, though the publication did not publish the message. The Epoch Times obtained the email and 199 other pages of Dr. Memoli’s emails through a Freedom of Information Act request. There were no indications that Dr. Fauci ever responded to Dr. Memoli.

Later in 2021, the NIAID’s parent agency, the U.S. National Institutes of Health (NIH), and all other federal government agencies began requiring COVID-19 vaccination, under direction from President Joe Biden.

In other messages, Dr. Memoli said the mandates were unethical and that he was hopeful legal cases brought against the mandates would ultimately let people “make their own healthcare decisions.”

“I am certainly doing everything in my power to influence that,” he wrote on Nov. 2, 2021, to an unknown recipient. Dr. Memoli also disclosed that both he and his wife had applied for exemptions from the mandates imposed by the NIH and his wife’s employer. While her request had been granted, his had not as of yet, Dr. Memoli said. It’s not clear if it ever was.

According to Dr. Memoli, officials had not gone over the bioethics of the mandates. He wrote to the NIH’s Department of Bioethics, pointing out that the protection from the vaccines waned over time, that the shots can cause serious health issues such as myocarditis, or heart inflammation, and that vaccinated people were just as likely to spread COVID-19 as unvaccinated people.

He cited multiple studies in his emails, including one that found a resurgence of COVID-19 cases in a California health care system despite a high rate of vaccination and another that showed transmission rates were similar among the vaccinated and unvaccinated.

Dr. Memoli said he was “particularly interested in the bioethics of a mandate when the vaccine doesn’t have the ability to stop spread of the disease, which is the purpose of the mandate.”

The message led to Dr. Memoli speaking during an NIH event in December 2021, several weeks after he went public with his concerns about mandating vaccines.

“Vaccine mandates should be rare and considered only with a strong justification,” Dr. Memoli said in the debate. He suggested that the justification was not there for COVID-19 vaccines, given their fleeting effectiveness.

Julie Ledgerwood, another NIAID official who also spoke at the event, said that the vaccines were highly effective and that the side effects that had been detected were not significant. She did acknowledge that vaccinated people needed boosters after a period of time.

The NIH, and many other government agencies, removed their mandates in 2023 with the end of the COVID-19 public health emergency.

A request for comment from Dr. Fauci was not returned. Dr. Memoli told The Epoch Times in an email he was “happy to answer any questions you have” but that he needed clearance from the NIAID’s media office. That office then refused to give clearance.

Dr. Jay Bhattacharya, a professor of health policy at Stanford University, said that Dr. Memoli showed bravery when he warned Dr. Fauci against mandates.

“Those mandates have done more to demolish public trust in public health than any single action by public health officials in my professional career, including diminishing public trust in all vaccines.” Dr. Bhattacharya, a frequent critic of the U.S. response to COVID-19, told The Epoch Times via email. “It was risky for Dr. Memoli to speak publicly since he works at the NIH, and the culture of the NIH punishes those who cross powerful scientific bureaucrats like Dr. Fauci or his former boss, Dr. Francis Collins.”

Tyler Durden Mon, 03/11/2024 - 17:40

Read More

Continue Reading

Government

Trump “Clearly Hasn’t Learned From His COVID-Era Mistakes”, RFK Jr. Says

Trump "Clearly Hasn’t Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President…

Published

on

Trump "Clearly Hasn't Learned From His COVID-Era Mistakes", RFK Jr. Says

Authored by Jeff Louderback via The Epoch Times (emphasis ours),

President Joe Biden claimed that COVID vaccines are now helping cancer patients during his State of the Union address on March 7, but it was a response on Truth Social from former President Donald Trump that drew the ire of independent presidential candidate Robert F. Kennedy Jr.

Robert F. Kennedy Jr. holds a voter rally in Grand Rapids, Mich., on Feb. 10, 2024. (Mitch Ranger for The Epoch Times)

During the address, President Biden said: “The pandemic no longer controls our lives. The vaccines that saved us from COVID are now being used to help beat cancer, turning setback into comeback. That’s what America does.”

President Trump wrote: “The Pandemic no longer controls our lives. The VACCINES that saved us from COVID are now being used to help beat cancer—turning setback into comeback. YOU’RE WELCOME JOE. NINE-MONTH APPROVAL TIME VS. 12 YEARS THAT IT WOULD HAVE TAKEN YOU.”

An outspoken critic of President Trump’s COVID response, and the Operation Warp Speed program that escalated the availability of COVID vaccines, Mr. Kennedy said on X, formerly known as Twitter, that “Donald Trump clearly hasn’t learned from his COVID-era mistakes.”

“He fails to recognize how ineffective his warp speed vaccine is as the ninth shot is being recommended to seniors. Even more troubling is the documented harm being caused by the shot to so many innocent children and adults who are suffering myocarditis, pericarditis, and brain inflammation,” Mr. Kennedy remarked.

“This has been confirmed by a CDC-funded study of 99 million people. Instead of bragging about its speedy approval, we should be honestly and transparently debating the abundant evidence that this vaccine may have caused more harm than good.

“I look forward to debating both Trump and Biden on Sept. 16 in San Marcos, Texas.”

Mr. Kennedy announced in April 2023 that he would challenge President Biden for the 2024 Democratic Party presidential nomination before declaring his run as an independent last October, claiming that the Democrat National Committee was “rigging the primary.”

Since the early stages of his campaign, Mr. Kennedy has generated more support than pundits expected from conservatives, moderates, and independents resulting in speculation that he could take votes away from President Trump.

Many Republicans continue to seek a reckoning over the government-imposed pandemic lockdowns and vaccine mandates.

President Trump’s defense of Operation Warp Speed, the program he rolled out in May 2020 to spur the development and distribution of COVID-19 vaccines amid the pandemic, remains a sticking point for some of his supporters.

Vice President Mike Pence (L) and President Donald Trump deliver an update on Operation Warp Speed in the Rose Garden of the White House in Washington on Nov. 13, 2020. (Mandel Ngan/AFP via Getty Images)

Operation Warp Speed featured a partnership between the government, the military, and the private sector, with the government paying for millions of vaccine doses to be produced.

President Trump released a statement in March 2021 saying: “I hope everyone remembers when they’re getting the COVID-19 Vaccine, that if I wasn’t President, you wouldn’t be getting that beautiful ‘shot’ for 5 years, at best, and probably wouldn’t be getting it at all. I hope everyone remembers!”

President Trump said about the COVID-19 vaccine in an interview on Fox News in March 2021: “It works incredibly well. Ninety-five percent, maybe even more than that. I would recommend it, and I would recommend it to a lot of people that don’t want to get it and a lot of those people voted for me, frankly.

“But again, we have our freedoms and we have to live by that and I agree with that also. But it’s a great vaccine, it’s a safe vaccine, and it’s something that works.”

On many occasions, President Trump has said that he is not in favor of vaccine mandates.

An environmental attorney, Mr. Kennedy founded Children’s Health Defense, a nonprofit that aims to end childhood health epidemics by promoting vaccine safeguards, among other initiatives.

Last year, Mr. Kennedy told podcaster Joe Rogan that ivermectin was suppressed by the FDA so that the COVID-19 vaccines could be granted emergency use authorization.

He has criticized Big Pharma, vaccine safety, and government mandates for years.

Since launching his presidential campaign, Mr. Kennedy has made his stances on the COVID-19 vaccines, and vaccines in general, a frequent talking point.

“I would argue that the science is very clear right now that they [vaccines] caused a lot more problems than they averted,” Mr. Kennedy said on Piers Morgan Uncensored last April.

“And if you look at the countries that did not vaccinate, they had the lowest death rates, they had the lowest COVID and infection rates.”

Additional data show a “direct correlation” between excess deaths and high vaccination rates in developed countries, he said.

President Trump and Mr. Kennedy have similar views on topics like protecting the U.S.-Mexico border and ending the Russia-Ukraine war.

COVID-19 is the topic where Mr. Kennedy and President Trump seem to differ the most.

Former President Donald Trump intended to “drain the swamp” when he took office in 2017, but he was “intimidated by bureaucrats” at federal agencies and did not accomplish that objective, Mr. Kennedy said on Feb. 5.

Speaking at a voter rally in Tucson, where he collected signatures to get on the Arizona ballot, the independent presidential candidate said President Trump was “earnest” when he vowed to “drain the swamp,” but it was “business as usual” during his term.

John Bolton, who President Trump appointed as a national security adviser, is “the template for a swamp creature,” Mr. Kennedy said.

Scott Gottlieb, who President Trump named to run the FDA, “was Pfizer’s business partner” and eventually returned to Pfizer, Mr. Kennedy said.

Mr. Kennedy said that President Trump had more lobbyists running federal agencies than any president in U.S. history.

“You can’t reform them when you’ve got the swamp creatures running them, and I’m not going to do that. I’m going to do something different,” Mr. Kennedy said.

During the COVID-19 pandemic, President Trump “did not ask the questions that he should have,” he believes.

President Trump “knew that lockdowns were wrong” and then “agreed to lockdowns,” Mr. Kennedy said.

He also “knew that hydroxychloroquine worked, he said it,” Mr. Kennedy explained, adding that he was eventually “rolled over” by Dr. Anthony Fauci and his advisers.

President Donald Trump greets the crowd before he leaves at the Operation Warp Speed Vaccine Summit in Washington on Dec. 8, 2020. (Tasos Katopodis/Getty Images)

MaryJo Perry, a longtime advocate for vaccine choice and a Trump supporter, thinks votes will be at a premium come Election Day, particularly because the independent and third-party field is becoming more competitive.

Ms. Perry, president of Mississippi Parents for Vaccine Rights, believes advocates for medical freedom could determine who is ultimately president.

She believes that Mr. Kennedy is “pulling votes from Trump” because of the former president’s stance on the vaccines.

“People care about medical freedom. It’s an important issue here in Mississippi, and across the country,” Ms. Perry told The Epoch Times.

“Trump should admit he was wrong about Operation Warp Speed and that COVID vaccines have been dangerous. That would make a difference among people he has offended.”

President Trump won’t lose enough votes to Mr. Kennedy about Operation Warp Speed and COVID vaccines to have a significant impact on the election, Ohio Republican strategist Wes Farno told The Epoch Times.

President Trump won in Ohio by eight percentage points in both 2016 and 2020. The Ohio Republican Party endorsed President Trump for the nomination in 2024.

“The positives of a Trump presidency far outweigh the negatives,” Mr. Farno said. “People are more concerned about their wallet and the economy.

“They are asking themselves if they were better off during President Trump’s term compared to since President Biden took office. The answer to that question is obvious because many Americans are struggling to afford groceries, gas, mortgages, and rent payments.

“America needs President Trump.”

Multiple national polls back Mr. Farno’s view.

As of March 6, the RealClearPolitics average of polls indicates that President Trump has 41.8 percent support in a five-way race that includes President Biden (38.4 percent), Mr. Kennedy (12.7 percent), independent Cornel West (2.6 percent), and Green Party nominee Jill Stein (1.7 percent).

A Pew Research Center study conducted among 10,133 U.S. adults from Feb. 7 to Feb. 11 showed that Democrats and Democrat-leaning independents (42 percent) are more likely than Republicans and GOP-leaning independents (15 percent) to say they have received an updated COVID vaccine.

The poll also reported that just 28 percent of adults say they have received the updated COVID inoculation.

The peer-reviewed multinational study of more than 99 million vaccinated people that Mr. Kennedy referenced in his X post on March 7 was published in the Vaccine journal on Feb. 12.

It aimed to evaluate the risk of 13 adverse events of special interest (AESI) following COVID-19 vaccination. The AESIs spanned three categories—neurological, hematologic (blood), and cardiovascular.

The study reviewed data collected from more than 99 million vaccinated people from eight nations—Argentina, Australia, Canada, Denmark, Finland, France, New Zealand, and Scotland—looking at risks up to 42 days after getting the shots.

Three vaccines—Pfizer and Moderna’s mRNA vaccines as well as AstraZeneca’s viral vector jab—were examined in the study.

Researchers found higher-than-expected cases that they deemed met the threshold to be potential safety signals for multiple AESIs, including for Guillain-Barre syndrome (GBS), cerebral venous sinus thrombosis (CVST), myocarditis, and pericarditis.

A safety signal refers to information that could suggest a potential risk or harm that may be associated with a medical product.

The study identified higher incidences of neurological, cardiovascular, and blood disorder complications than what the researchers expected.

President Trump’s role in Operation Warp Speed, and his continued praise of the COVID vaccine, remains a concern for some voters, including those who still support him.

Krista Cobb is a 40-year-old mother in western Ohio. She voted for President Trump in 2020 and said she would cast her vote for him this November, but she was stunned when she saw his response to President Biden about the COVID-19 vaccine during the State of the Union address.

I love President Trump and support his policies, but at this point, he has to know they [advisers and health officials] lied about the shot,” Ms. Cobb told The Epoch Times.

“If he continues to promote it, especially after all of the hearings they’ve had about it in Congress, the side effects, and cover-ups on Capitol Hill, at what point does he become the same as the people who have lied?” Ms. Cobb added.

“I think he should distance himself from talk about Operation Warp Speed and even admit that he was wrong—that the vaccines have not had the impact he was told they would have. If he did that, people would respect him even more.”

Tyler Durden Mon, 03/11/2024 - 17:00

Read More

Continue Reading

Government

Mathematicians use AI to identify emerging COVID-19 variants

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants…

Published

on

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.

Credit: source: https://phil.cdc.gov/Details.aspx?pid=23312

Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.

The framework combines dimension reduction techniques and a new explainable clustering algorithm called CLASSIX, developed by mathematicians at The University of Manchester. This enables the quick identification of groups of viral genomes that might present a risk in the future from huge volumes of data.

The study, presented this week in the journal PNAS, could support traditional methods of tracking viral evolution, such as phylogenetic analysis, which currently require extensive manual curation.

Roberto Cahuantzi, a researcher at The University of Manchester and first and corresponding author of the paper, said: “Since the emergence of COVID-19, we have seen multiple waves of new variants, heightened transmissibility, evasion of immune responses, and increased severity of illness.

“Scientists are now intensifying efforts to pinpoint these worrying new variants, such as alpha, delta and omicron, at the earliest stages of their emergence. If we can find a way to do this quickly and efficiently, it will enable us to be more proactive in our response, such as tailored vaccine development and may even enable us to eliminate the variants before they become established.”

Like many other RNA viruses, COVID-19 has a high mutation rate and short time between generations meaning it evolves extremely rapidly. This means identifying new strains that are likely to be problematic in the future requires considerable effort.

Currently, there are almost 16 million sequences available on the GISAID database (the Global Initiative on Sharing All Influenza Data), which provides access to genomic data of influenza viruses.

Mapping the evolution and history of all COVID-19 genomes from this data is currently done using extremely large amounts of computer and human time.

The described method allows automation of such tasks. The researchers processed 5.7 million high-coverage sequences in only one to two days on a standard modern laptop; this would not be possible for existing methods, putting identification of concerning pathogen strains in the hands of more researchers due to reduced resource needs.

Thomas House, Professor of Mathematical Sciences at The University of Manchester, said: “The unprecedented amount of genetic data generated during the pandemic demands improvements to our methods to analyse it thoroughly. The data is continuing to grow rapidly but without showing a benefit to curating this data, there is a risk that it will be removed or deleted.

“We know that human expert time is limited, so our approach should not replace the work of humans all together but work alongside them to enable the job to be done much quicker and free our experts for other vital developments.”

The proposed method works by breaking down genetic sequences of the COVID-19 virus into smaller “words” (called 3-mers) represented as numbers by counting them. Then, it groups similar sequences together based on their word patterns using machine learning techniques.

Stefan Güttel, Professor of Applied Mathematics at the University of Manchester, said: “The clustering algorithm CLASSIX we developed is much less computationally demanding than traditional methods and is fully explainable, meaning that it provides textual and visual explanations of the computed clusters.”

Roberto Cahuantzi added: “Our analysis serves as a proof of concept, demonstrating the potential use of machine learning methods as an alert tool for the early discovery of emerging major variants without relying on the need to generate phylogenies.

“Whilst phylogenetics remains the ‘gold standard’ for understanding the viral ancestry, these machine learning methods can accommodate several orders of magnitude more sequences than the current phylogenetic methods and at a low computational cost.”


Read More

Continue Reading

Trending